vs

Side-by-side financial comparison of Smart Sand, Inc. (SND) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

VERACYTE, INC. is the larger business by last-quarter revenue ($140.6M vs $86.0M, roughly 1.6× Smart Sand, Inc.). VERACYTE, INC. runs the higher net margin — 29.3% vs 1.4%, a 27.9% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs -5.8%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $20.4M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs 1.8%).

Sand 9 is a fabless Micro-electromechanical system (MEMS) company based in Cambridge, Massachusetts. Sand 9 developed a piezoelectric MEMS resonator to serve as an alternative for quartz timing devices in applications such as smart phones, low-power wireless devices, and communications infrastructure equipment.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

SND vs VCYT — Head-to-Head

Bigger by revenue
VCYT
VCYT
1.6× larger
VCYT
$140.6M
$86.0M
SND
Growing faster (revenue YoY)
VCYT
VCYT
+24.4% gap
VCYT
18.5%
-5.8%
SND
Higher net margin
VCYT
VCYT
27.9% more per $
VCYT
29.3%
1.4%
SND
More free cash flow
VCYT
VCYT
$28.4M more FCF
VCYT
$48.8M
$20.4M
SND
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
1.8%
SND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SND
SND
VCYT
VCYT
Revenue
$86.0M
$140.6M
Net Profit
$1.2M
$41.1M
Gross Margin
13.0%
72.5%
Operating Margin
-3.1%
26.4%
Net Margin
1.4%
29.3%
Revenue YoY
-5.8%
18.5%
Net Profit YoY
-68.5%
704.8%
EPS (diluted)
$0.03
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SND
SND
VCYT
VCYT
Q4 25
$86.0M
$140.6M
Q3 25
$92.8M
$131.9M
Q2 25
$85.8M
$130.2M
Q1 25
$65.6M
$114.5M
Q4 24
$91.4M
$118.6M
Q3 24
$63.2M
$115.9M
Q2 24
$73.8M
$114.4M
Q1 24
$83.1M
$96.8M
Net Profit
SND
SND
VCYT
VCYT
Q4 25
$1.2M
$41.1M
Q3 25
$3.0M
$19.1M
Q2 25
$21.4M
$-980.0K
Q1 25
$-24.2M
$7.0M
Q4 24
$3.7M
$5.1M
Q3 24
$-98.0K
$15.2M
Q2 24
$-430.0K
$5.7M
Q1 24
$-216.0K
$-1.9M
Gross Margin
SND
SND
VCYT
VCYT
Q4 25
13.0%
72.5%
Q3 25
16.1%
69.2%
Q2 25
10.4%
69.0%
Q1 25
4.2%
69.5%
Q4 24
14.7%
66.4%
Q3 24
10.3%
68.2%
Q2 24
17.7%
68.1%
Q1 24
14.2%
64.5%
Operating Margin
SND
SND
VCYT
VCYT
Q4 25
-3.1%
26.4%
Q3 25
5.8%
17.4%
Q2 25
-0.1%
-4.0%
Q1 25
-10.8%
2.5%
Q4 24
3.9%
3.5%
Q3 24
-7.8%
10.4%
Q2 24
4.8%
4.0%
Q1 24
0.9%
-4.8%
Net Margin
SND
SND
VCYT
VCYT
Q4 25
1.4%
29.3%
Q3 25
3.2%
14.5%
Q2 25
24.9%
-0.8%
Q1 25
-37.0%
6.2%
Q4 24
4.1%
4.3%
Q3 24
-0.2%
13.1%
Q2 24
-0.6%
5.0%
Q1 24
-0.3%
-1.9%
EPS (diluted)
SND
SND
VCYT
VCYT
Q4 25
$0.03
$0.50
Q3 25
$0.08
$0.24
Q2 25
$0.54
$-0.01
Q1 25
$-0.62
$0.09
Q4 24
$0.10
$0.07
Q3 24
$0.00
$0.19
Q2 24
$-0.01
$0.07
Q1 24
$-0.01
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SND
SND
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$22.6M
$362.6M
Total DebtLower is stronger
$15.0M
Stockholders' EquityBook value
$239.7M
$1.3B
Total Assets
$340.0M
$1.4B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SND
SND
VCYT
VCYT
Q4 25
$22.6M
$362.6M
Q3 25
$5.1M
$315.6M
Q2 25
$4.3M
$219.5M
Q1 25
$5.1M
$186.1M
Q4 24
$1.6M
$239.1M
Q3 24
$7.2M
$274.1M
Q2 24
$6.3M
$235.9M
Q1 24
$4.6M
$209.2M
Total Debt
SND
SND
VCYT
VCYT
Q4 25
$15.0M
Q3 25
$14.3M
Q2 25
$23.5M
Q1 25
$13.7M
Q4 24
$14.7M
Q3 24
$15.7M
Q2 24
$17.1M
Q1 24
$25.5M
Stockholders' Equity
SND
SND
VCYT
VCYT
Q4 25
$239.7M
$1.3B
Q3 25
$239.9M
$1.3B
Q2 25
$240.5M
$1.2B
Q1 25
$219.9M
$1.2B
Q4 24
$243.8M
$1.2B
Q3 24
$243.6M
$1.2B
Q2 24
$242.9M
$1.1B
Q1 24
$242.5M
$1.1B
Total Assets
SND
SND
VCYT
VCYT
Q4 25
$340.0M
$1.4B
Q3 25
$343.1M
$1.4B
Q2 25
$345.8M
$1.3B
Q1 25
$326.9M
$1.3B
Q4 24
$341.5M
$1.3B
Q3 24
$335.8M
$1.3B
Q2 24
$341.8M
$1.2B
Q1 24
$349.3M
$1.2B
Debt / Equity
SND
SND
VCYT
VCYT
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.06×
Q4 24
0.06×
Q3 24
0.06×
Q2 24
0.07×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SND
SND
VCYT
VCYT
Operating Cash FlowLast quarter
$22.4M
$52.6M
Free Cash FlowOCF − Capex
$20.4M
$48.8M
FCF MarginFCF / Revenue
23.7%
34.7%
Capex IntensityCapex / Revenue
2.3%
2.7%
Cash ConversionOCF / Net Profit
18.99×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$32.5M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SND
SND
VCYT
VCYT
Q4 25
$22.4M
$52.6M
Q3 25
$18.2M
$44.8M
Q2 25
$-5.1M
$33.6M
Q1 25
$8.7M
$5.4M
Q4 24
$1.0M
$24.5M
Q3 24
$5.8M
$30.0M
Q2 24
$14.9M
$29.6M
Q1 24
$-3.9M
$-9.0M
Free Cash Flow
SND
SND
VCYT
VCYT
Q4 25
$20.4M
$48.8M
Q3 25
$14.8M
$42.0M
Q2 25
$-7.8M
$32.3M
Q1 25
$5.2M
$3.5M
Q4 24
$-840.0K
$20.4M
Q3 24
$3.7M
$27.7M
Q2 24
$13.5M
$26.8M
Q1 24
$-5.5M
$-11.1M
FCF Margin
SND
SND
VCYT
VCYT
Q4 25
23.7%
34.7%
Q3 25
15.9%
31.8%
Q2 25
-9.1%
24.8%
Q1 25
7.9%
3.1%
Q4 24
-0.9%
17.2%
Q3 24
5.8%
23.9%
Q2 24
18.3%
23.4%
Q1 24
-6.6%
-11.5%
Capex Intensity
SND
SND
VCYT
VCYT
Q4 25
2.3%
2.7%
Q3 25
3.6%
2.1%
Q2 25
3.1%
1.0%
Q1 25
5.4%
1.6%
Q4 24
2.1%
3.5%
Q3 24
3.4%
1.9%
Q2 24
1.8%
2.4%
Q1 24
2.0%
2.2%
Cash Conversion
SND
SND
VCYT
VCYT
Q4 25
18.99×
1.28×
Q3 25
6.05×
2.34×
Q2 25
-0.24×
Q1 25
0.76×
Q4 24
0.28×
4.80×
Q3 24
1.98×
Q2 24
5.16×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SND
SND

Sand$85.1M99%
Smart Systems Segment$980.0K1%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons